Form 8-K · Current Report · Filed 2024-07-29
Guardant Health's Shield Blood Test Approved by FDA for CRC Screening
Guardant Health, Inc. announced on July 29, 2024, that the U.S. Food and Drug Administration (FDA) has approved the Company's Shield blood test to screen for colorectal cancer in adults age 45 and older who are at average risk for the disease. This approval makes Shield the first blood test to be approved by the FDA as a primary screening option for colorectal cancer, enabling healthcare providers to offer it as a convenient alternative to other non-invasive screening methods. The approval is based on results from a registrational study with over 20,000 patients, demonstrating the test's 83% sensitivity and 90% specificity for detecting colorectal cancer. The Shield test is expected to be covered for eligible Medicare beneficiaries and will likely expand commercial insurance coverage following anticipated guideline inclusion by major health organizations.
- Filer
- Guardant Health Inc. GH · NASDAQ
- Filed
- Accession
- 0001193125-24-186674
- CIK
- 0001576280
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Other Events
Financial Statements and Exhibits
Market reaction
Close before filing
$33.00
Next session
+10.0%
Since filing
+390.9%
Latest close
$161.99
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from GH reporting the same item, with the next session's move:
Exhibits (1)
About Guardant Health Inc.
Guardant Health Inc. is an innovative biotechnology company specializing in the development and commercialization of precision oncology diagnostics. This company is recognized for its groundbreaking work in non-invasive cancer detection through liquid biopsy technologies, which involve analyzing circulating tumor DNA in blood samples. Guardant Health’s primary function is to provide oncologists and researchers with critical tools and data to better understand cancer, tailor treatments, and monitor disease progression, potentially improving patient outcomes significantly. Guardant Health operates prominently in the healthcare and biotechnology sector, significantly impacting fields such as cancer research and personalized medicine. Their products and services are vital for facilitating early detection of cancer, identifying treatment options, and offering companion diagnostics for pharmaceutical developments. In the financial market, Guardant Health represents an important player within the precision medicine landscape, influencing investment within the biotechnology and healthcare sectors. Founded in 2012 and headquartered in Redwood City, California, the company continues to expand its portfolio and advance its technologies, playing a pivotal role in the fight against cancer at a global level.
Never miss another GH filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.